Hannah Went

🌿 Advocating for Cannabinoid Therapies 🏥" In a recent Television interview, I emphasized the crucial role of education for doctors prescribing Cannabinoid Therapies. -The Ministry of Health in Panama hasn't authorized any cannabis products, and those bought on the streets lack official approval and quality control. -I cautioned patients against purchasing unapproved cannabis products due to potential health risks like heavy metals, fungus, and pesticides, among many other risks. -In Panama, only MDs are allowed to prescribe Medical Cannabis. -Education is crucial to the broader acceptance of cannabis as medicine. As someone who has taught thousands of medical professionals globally, they will not prescribe unless they are correctly educated about the benefits and risks of cannabinoid therapies. My commentary starts at 1:30 in Spanish in the video below. Please support our community content by liking and commenting on this post. Please follow me on Instagrm: drsandracarrillo for unique content not posted to Linkedin. Twittr: md_carrillo Medicannips IPS Medical Cannabis Clinics, Colombia. https://lnkd.in/guCTjCMM #cannabis #marijuana #medicalcannabis #cannabisscience #medicine  #thc #cbd  #education #Health #Panama Asociación Médica Colombiana de Cannabis Medicinal #Asomedccam

80

12 Comments

Well, now it's front and center from Grandmaster JB himself.. We're excited in our part of the world to see how this impacts research freedom and ailment based solution development and access to capital around it. Hoping to play a significant role in sharing the research learnings HempStreet and some of our stellar industry colleagues in India have come accross, especially since we were from inception of the industry's current form and continue to be, purely medical. A few of us have clinical trials under way and at HempStreet we're at the decisive end of our pioneering trial on Dysmenorrhea. The US is usually the holy grail for business growth and the global south is for impact. However, this particular ailment merges the two accross the world, impacting 25-30% of the global population. Unlike consumer durables and impulse e-commerce purchases, menstrual health doesn't see per capita GDP.. Will we see a Lee Fixel kind of maverick roll up with American $$ to turbocharge the medical cannabis industry in India, just like we saw for ecommerce? Overtly optimistic? I guess it's the only way to be given how we've all gotten this far in the Indian Medcann ecosystem with zero VC money. American friends. Your view? #reclassification #USA #medicalcannabis #india #dysmenorrhea #joebiden https://lnkd.in/gud_M-Uj

20

2 Comments

Anyone looking for CBGV or CBDV flower? CBGV is 1:1 CBG:CBGV THC free and CBDV 1:1 compliant. Will be greenhouse grown. Contemplating how many plants to get in the ground within the next week or two.

14

Read our latest research & find out which cannabis cultivars showed resistance to Hop Lantent Viroid (HLVd), a widespread and catastrophic disease 🦠 Here at StateHouse Holdings we executed a research project examining the effects of HLVd on 12 cannabis varieties at different growth stages, and the results were fascinating! 🤔 It was a pleasure to work on this collaborative project with Tassa Saldi, PhD with TUMI Genomics and Ben Niehaus with SpexAI GmbH Research like this is what will move the needle in the industry, drive breeding efforts, and improve cannabis cultivation everywhere. 💪 More to come! #cannabis #cultivation #plantpathology #viroid #cannabisindustry

18

1 Comment

Learn about the dangers posed by unregulated Delta-8 and other intoxicating, hemp-derived, synthetic cannabinoid products which are widely available throughout our our communities. Please watch this short video to better understand the risks these products pose to our children's health and the public's well-being, then contact your Ohio State Representative and State Senator and let them know that we want regulation of these products in Ohio. https://lnkd.in/eZYFJQxn https://lnkd.in/gEs3Gx7i

8

7 Comments

DEA reclassifying Cannabis and cannabinoid-based medications from Schedule I to III is a HUGE deal. From medical POV, it allows for: 1. Further better quality cannabis research (not just self-reported data) 2. Quality assurance in product safety and standardization in prescribing meds to patients 3. Health insurances to cover FDA-approved products 4. Reduction in opioid use. Still lots more work to go, but a pivotal step in using scientific, evidence-based natural medicines to ease pain and suffering in the care of our patients. https://lnkd.in/eZFtMdTt

11

Hop latent viroid (#HLVd) #infection lowers the #commercial #value of #cannabis by reducing #flower #harvest #weight, #thc concentration, and #terpene #production. Unlike other #microbial #contaminants including #yeast , #mold , and pathogenic #bacteria, HLVd is not subject to #regulatory #compliance #testing due to the absence of known #human #safety concerns. However, because of the #financial #losses associated with HLVd #infection , cannabis #cultivators are advised to adopt a tiered #approach to #safeguard against HLVd and other #microbial #contaminants to reduce the #risk or spread of #infection. These strategies include implementing (in order of increasing complexity and effort): basic #biosecurity standard #operating #procedures , non-burdensome #environmental #monitoring plans (EMP) and rational Hazard Analysis and Control Point (#HACCP) plans. Remarkably, these #strategies not only #shield against HLVd but also confer enhanced #protection against other #financially #detrimental #microbial #contaminants such as #yeast , #mold , and pathogenic #bacteria. Consequently, the #adoption of these #protective #measures yields additional #benefits, including the #production of a higher #quality #cannabis #product that commands premium #pricing, a #reduction in #microbial #contaminant test failures without reliance on a kill-step, and the fulfillment of a crucial element for future Good Manufacturing Practices (GMP) certification. https://lnkd.in/eqenAG9H

1

I’ve been on an outreach mission for the past 3 weeks to better understand current needs, strategy, and risks in licensed cannabis testing laboratories.  For labs that engaged (~20%), ALL BUT TWO (2) claimed: 1)    Their lab has no current operational needs. 2)    Their lab has no strategic objectives they are trying to meet. 3)    Their lab has no regulatory or compliances risks they are concerned about. 4)    Their lab did not see a need to explore potential solutions because nothing is frustrating them. So… Sales and marketing is killing it with 50%+ YOY growth of 3+ yrs?  The lab team is developing new, innovative, non-regulated tests for which a premium can be charged?  Culture is great with an employee turnover <10% annually? You’ve implemented smart automation to reduce obvious sources of variability and time suck? TAT is approaching 24 hrs with a repeat rate <1%? The lab is in a state of continual readiness for state & quality audits? Sorry, but that sounds too good to be true. If you’d like to talk about how to meet some of those mission critical OKR’s in a timely and cost-effective manner, I encourage you to schedule a free, confidential, no pressure call with E4 Bioscience.  E4 has helped over 50+ cannabis labs develop and meet important goals.

14

9 Comments

Investing in companies that fill needs for health systems is a growth opportunity for both delivery organizations and start ups. Some systems are jumping in on their own, while others are partnering with like minded systems or with established VC firms. While this is a relatively new trend for systems, health plans have been making similar bets for many years. The benefits of becoming a health system portfolio company can be significant. Data, access to beta populations and real world coaching can be extremely beneficial. Start ups get mentoring and systems have to ability to leverage outside resources to solve relevant business problems. I predict a booming business!

4

Major breakthrough: We've entered the era of the Cannabis Pangenome! This fantastic new preprint is very information dense, so I'm going to break it down all week. This is a great example of how private sector and academic collaborations can drive Cannabis science knowledge. A pangenome of 181 new and 12 prior genomes has been released from Oregon CBD, Salk Institute for Biological Studies, and Oregon State University. What is a Pangenome and why is it a big deal? Lets start with a genome and work our way up. A genome is the complete set of genetic material in a single organism. Cannabis, like humans, is diploid - meaning it gets a set of information from a mother and father. This information is spread throughout chromosomes - 9 autosomes and an X/Y sex chromosome pair. Sequencing and mapping even an individual genome has been challenging. The first genomes relied heavily on short-read sequencing, which sequences 100-200 base pair fragments. It was already known that Cannabis had highly repetitive sequences, so the process of "assembly" - putting those fragments together into a single long sequence across the 10 chromosomes was difficult to say the least. In 2018 the "reference" genome (cs10) was released using some early long-read sequencing technology (Oxford Nanopore) to help assemble those fragments. Long read sequencing allows for longer chunks of sequences to be assembled. Being diploid poses more challenges, especially because these strains aren't inbred. This means that the genetic makeup and structure of the mom chromosomes differ from that of the dad chromosomes. Enter the "phasing" technique, which attempts to assign and assemble exactly how the differences in the mom and dad chromosomes. This study used "trio phasing" - sequencing of both parents and their offspring (posted figure). By this technique, the sequences can be "phased" to each copy of the parental chromosome. A pangenome is the collection of all genes from all strains within a species and is a multi-genome assembly that can capture a species' genetic diversity. *The key here is diversity* A pangenome allows the comparison of diversity of genetic makeup in a genepool. The hope is to represent all of cannabis genetic diversity, and learn how that diversity contributes to what we see and what is yet to be seen. Spoiler: there is a lot yet to be seen and discovered. This beginning of the pangenome has 156 biological samples, including 42 trio phased. Congrats to the all-star cast of Ryan Lynch, Lillian Padgitt-Cobb, Andrea Garfinkel, Brian Knaus, Nolan Hartwick, Nicholas Allsing, Anthony Aylward, Allen Mamerto, Justine Kitony, Kelly Colt, Emily Murray, Tiffany Duong, Aaron Trippe, Seth Crawford, Kelly Vining, and Todd Michael. Disclaimer: I'm not involved in any way with this pangenome or with any of these groups. This is a pre-print. I have not vetted the data or the pangenome in depth yet. #BetterCannabisThroughScience Link in comments

128

23 Comments

Maxx Chatsko recently wrote the article about Ginkgo Bioworks below and he got much of it right but not all. He noted going public via a SPAC made the stock price at issue, $10, and they had over 1.45 billion shares outstanding. Having a large number of shares is not an issue, not living up to your forecasts is the real issue. From a stock performance perspective they really have two issues, one is dilution that he notes. He should have pointed out GB has been buying companies and technologies with their stock as though it is free! The cost is dilution which added almost 50% more shares outstanding but not any revenue or ebitda. If a share based acquisition is not accretive to earnings, the company will quickly be under pressure and the stock will drop. The other issue is definitely burning cash while not having a clear line of sight to turning this around. They have over 1,200 employees. While they had almost $1 billion in the bank at the beginning of the year, you can do the math on the cost of this many skilled employees. And I fully agree with him, once you reverse split your stock to raise the price, it typically only continues to go down until you stop your burn. The company has to reduce employees and put in place a strategy to stop the burn or it will continue to tumble. I should also point out many funds have to automatically divest stocks below $1 or sometimes $2. https://lnkd.in/gVyJZPJd

3

How many cannabis and hemp products exist? How many possible product variations might there be? This article attempts to estimate these numbers. While definitive statements on this subject are not possible, this article aims to offer a thoughtful exploration. My objective with these calculations is modest: to share my thinking and understanding of this topic in the hope that it will stimulate further exploration (and maybe collaborative data collection and analysis efforts). And, perhaps through my errors—though I hope they are few in this article—bring new insights. https://lnkd.in/emE6Hn5G

23

5 Comments

As I prepare for CANNRA this week in Minneapolis - where cannabis regulators and cannabis patient/consumer advocates from around the country are congregating - I wanted to surface a piece of public testimony I submitted to the New Jersey Cannabis Regulatory Commission on behalf of the New Jersey Department of State's Cannabis Training Academy. The NJ CRC was calling for public commentary on how future cannabis tax revenues generated by the state's social equity excise fee should be used. This is the first time another NJ state agency has submitted public testimony to the CRC with suggestions on cannabis tax revenue use. Hoping other states can take these suggestions to heart as they determine how to use their cannabis tax revenue. My first suggestion is, in my opinion, one of the most important: Cannabis tax revenue generated by New Jersey's social equity excise fee should be used for the coverage of, or reimbursement of, payments for wrap-around reentry services for adults and juveniles (as in financial support set aside to support reentry programs, housing programs for returning citizens, mental health services, workforce/job/mentor services, transportation, education, and food assistance for returning citizens) for those who’ve have been released, or will be released from incarceration for a prior cannabis conviction. This coverage and reimbursement includes for any legal aid or penalties/fines paid for a previous cannabis conviction and/or prior cases.

13

The good news: Rescheduling cannabis to Schedule III is an acknowledgement by the federal government that cannabis has an accepted medical use and may lawfully be dispensed by prescription. The bad news: Only 2% of doctors have dosing knowledge, which has historically left 98% of all patients using cannabis-as-a-medicine to self-medicate. Not ideal or safe. The exciting news: ExstoBio has been busy over the past 2 years building a solution to help doctors facilitate science-based, data-driven medical cannabis care from start-to-finish.

42

1 Comment

🌿 Have you listened to @Science vs. Podcast's Cannabis episode? �� Indica, Sativa, and Hybrid? It's good to be reminded occasionally that this industry is still in its infancy and still needs time to "grow up." Let's back things up with science... HIGH-NOT 🚀 Did you know that recent research suggests that the distinctions between cannabis strains might not be as clear-cut as we once thought? Genetic analysis revealed inconsistencies, challenging the traditional classifications of Indica and Sativa. Plus, the notion that CBD can counteract THC-induced paranoia? Turns out, the evidence isn't quite there. So, before you buy into the hype, let's take a step back and examine the facts. The cannabis landscape is evolving, and it's crucial to stay informed about what the science says. 🌱💡HIGH-NOT #easeyourhigh #ScienceVs #Cannabis #BackedByScience https://lnkd.in/eqJqQXxs

5

Unveiling New Marijuana - Cannabis Cannabinoids: THCP and CBDP Marijuana research is an ever-evolving area, continuously revealing brand-new cannabinoids with one-of-a-kind residential or commercial properties. Amongst the current explorations are THCP (tetrahydrocannabiphorol) and CBDP (cannabidiphorol). These unique substances promise to reshape our understanding of cannabis and its prospective benefits. This blog delves into the fascinating world of THCP and CBDP, exploring their chemical structures, prospective benefits, present research study, and future ramifications. With extensive testing from accredited labs like a Third Party CBDTesting Lab, these discoveries hold terrific pledge for both the cannabis market and medical applications. What are THCP and CBDP? THCP and CBDP Defined THCP: THCP, or tetrahydrocannabiphorol, is a newly uncovered cannabinoid that resembles THC yet is possibly a lot more potent. This increased effectiveness is thought to arise from its distinct chemical structure, which allows it to connect extra highly with the body's endocannabinoid system. THCP's discovery opens the door to brand-new possibilities in cannabis-based therapies, specifically in locations where high strength is helpful. CBDP: CBDP, or cannabidiphorol, is one more newly recognized cannabinoid that carefully resembles CBD. Nonetheless, minor variations in its framework may lead to one-of-a-kind therapeutic advantages not seen with conventional CBD. This could consist of enhanced anti-inflammatory properties or various other health advantages, making it a considerable discover for clinical research and item development. Continue…. Link Here⬇️ https://lnkd.in/gaN5UF_b JUNE 19, 2024, 1:47 AM #cannabinoid #cannabis #researchanddevelopment #THCP #CBDP

44

22 Comments

Is HLVd Killing the Cannabis Industry? Check out my latest article on HLVD and if you want to read the entire article with a free eradication plan/SOP head over to growworld.com! Here's a sneak peak: Understanding Hop Latent Viroid in Cannabis: Identification and Management Hop Latent Viroid (HLVd) stands as a prominent concern for cannabis cultivators globally. Despite its diminutive size, this infectious agent possesses the capability to inflict significant harm on cannabis crops if left unaddressed. Acquiring a comprehensive grasp of HLVd, discerning its symptoms, and executing effective management protocols are imperative for upholding the health and productivity of cannabis plants. What is Hop Latent Viroid (HLVd)? HLVd represents a single-stranded, circular RNA molecule classified within the Pospiviroidae family. Contrary to its nomenclature, this viroid impacts not only hop plants but also a variety of other crops, including cannabis. Devoid of a protein coat, HLVd relies on the host's cellular machinery for replication and primarily disseminates through contaminated plant material, tools, and water sources. Symptoms of HLVd Infection in Cannabis: Detecting HLVd infection in cannabis plants can be intricate due to symptoms that may vary based on factors such as strain, environmental conditions, and coexisting pathogens. Nevertheless, several common indicators may hint at the presence of HLVd: Stunted Growth: Infected plants typically manifest diminished vigor and growth in comparison to healthy counterparts, characterized by delayed development and reduced overall size. Leaf Deformities: Anomalies in leaf growth, encompassing curling, twisting, and cupping, are common in infected plants, affecting both new growth and mature foliage. Discoloration: Leaf yellowing or mottling, particularly along veins, serves as a prevalent symptom of HLVd infection, with variations in intensity and distribution. Reduced Yield: Infected plants commonly exhibit lower yields relative to healthy ones, with decreased flower and resin production significantly impacting the economic viability of cannabis cultivation. Identifying HLVd: While visual inspection may offer initial insights, definitive diagnosis of HLVd necessitates laboratory testing. Techniques like reverse transcription-polymerase chain reaction (RT-PCR) or loop-mediated isothermal amplification (LAMP) can identify viroid-specific RNA sequences in plant tissue samples. Management Strategies: Upon detecting HLVd, immediate action is imperative to curtail its spread and minimize crop damage. Effective management strategies encompass: Quarantine and Removal: Swiftly isolate infected plants to prevent further contamination. Eliminate and dispose of affected individuals, including roots, stems, and leaves, to eradicate potential sources of HLVd transmission. Check out the rest of my article on LinkedIn and growworld.com!

49

7 Comments

Link to get your guide —> https://lnkd.in/gmaxSnGE Written by Shalisa Chamberlain- RVT, Veterinary CBD consulting, CEO Furry Faces CBD. Learn more about Shalisa —> https://lnkd.in/dcKp-Y_A

4